Inhale gains respiratory drug delivery technology:
This article was originally published in Clinica
Inhale Therapeutic Systems is to acquire Alliance Pharmaceutical's PulmoSpheres particle and particle processing technology for use in respiratory drug delivery for $15 million in cash and $5 million in Inhale shares. San Carlos, California-based Inhale will get $5 million of Alliance stock. Alliance will also get future milestone payments and retains the right to develop up to two respiratory products based on the technology. The technology is designed to enhance the efficiency and reproducibility of drugs which are delivered in propellant-based metered-dose inhalers and dry powder inhalers.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.